◆英語タイトル:OptiNose US Inc (OPTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8225
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
OptiNose US Inc (OptiNose) is a specialty pharmaceutical company that develops and delivers new pipeline drugs through intranasal deposition of medications. The company offers products such as XHANCE fluticasone propionate and ONZETRA sumatriptan nasal powder. Its products are used in the therapeutic areas of nasal inflammatory diseases, nasal congestion and obstruction, chronic rhinosinusitis, facial pain and pressure, drainage and postnasal drip, nasal polyps, autism, narcolepsy and Parkinson’s diseases. OptiNose develops powder delivery device with a disposable drug-containing section and liquid delivery device for medication-carrying airflow into nasal cavity. The company also develops exhalation delivery system technology used for the treatment of neurological or psychiatric disorders, and central nervous system disorders. It has operations in the US, Norway and the UK. OptiNose is headquartered in Yardley, Pennsylvania, the US.
OptiNose US Inc (OPTN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OptiNose US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 9
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OptiNose US Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
OptiNose Raises USD37 Million in Series D Financing 11
Optinose Raises USD30 Million in Venture Financing 12
Private Equity 13
Optinose to Raise USD100 Million in Private Placement of Notes Due 2023 13
Partnerships 15
OptiNose US Enters Into Collaboration with Oslo University Hospital, SINTEF and Smerud Medical Research International 15
Equity Offering 16
Optinose Raises USD55.6 Million in Public Offering of Share 16
Optinose to Raise Funds through Public Offering of Shares 18
OptiNose Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 19
OptiNose Raises USD138 Million in IPO of Shares 20
Debt Offering 22
Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2020 22
Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2017 23
OptiNose US Inc – Key Competitors 24
OptiNose US Inc – Key Employees 25
OptiNose US Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 14, 2018: Optinose reports second quarter 2018 financial results and recent operational highlights 27
May 14, 2018: Optinose Announces First Quarter 2018 Financial Results 29
Mar 13, 2018: Optinose Announces Fourth Quarter and Full Year 2017 Financial Results 31
Nov 27, 2017: Optinose Reports Third Quarter 2017 Financial Results and Recent Operating Highlights 33
Corporate Communications 35
Feb 22, 2018: Optinose names Sandra L. Helton as Director and Chairperson of the Company’s Audit Committee 35
Feb 09, 2017: OptiNose appoints chief legal officer 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
OptiNose US Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OptiNose US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OptiNose US Inc, Deals By Therapy Area, 2012 to YTD 2018 8
OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 9
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OptiNose Raises USD37 Million in Series D Financing 11
Optinose Raises USD30 Million in Venture Financing 12
Optinose to Raise USD100 Million in Private Placement of Notes Due 2023 13
OptiNose US Enters Into Collaboration with Oslo University Hospital, SINTEF and Smerud Medical Research International 15
Optinose Raises USD55.6 Million in Public Offering of Share 16
Optinose to Raise Funds through Public Offering of Shares 18
OptiNose Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 19
OptiNose Raises USD138 Million in IPO of Shares 20
Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2020 22
Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2017 23
OptiNose US Inc, Key Competitors 24
OptiNose US Inc, Key Employees 25
OptiNose US Inc, Subsidiaries 26
List of Figures
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 9